We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
- Authors
Ronner, E; Boersma, E; Akkerhuis, K M; Harrington, R A; Lincoff, A M; Deckers, J W; Karsch, K; Kleiman, N S; Vahanian, A; Topol, E J; Califf, R M; Simoons, M L
- Abstract
Many patients with acute coronary syndromes are offered percutaneous coronary intervention. However, the appropriate indications for, and optimal timing of, such procedures are uncertain. We analysed timing of intervention and associated events (death and myocardial infarction) in the PURSUIT trial in which 9461 patients received a platelet glycoprotein IIb/IIIa inhibitor, eptifibatide, or placebo for 72 h. Other treatment was left to the investigators. 2430 patients underwent percutaneous coronary intervention within 30 days. Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients.
- Publication
European heart journal, 2002, Vol 23, Issue 3, p239
- ISSN
0195-668X
- Publication type
Journal Article
- DOI
10.1053/euhj.2001.2736